DEF 14C: Biotech Firm Secures $3 Million Capital Infusion Amidst Going Concern Doubts

A pharmaceutical company has completed a $3 million private placement of convertible preferred stock and warrants, approved by its majority shareholder, to fund operations and address significant financial uncertainties.

Summary

• Cyclacel Pharmaceuticals, Inc. entered into a Securities Purchase Agreement on June 20, 2025, with accredited investors to raise $3,000,000.
• The company sold 3,000,000 shares of Series F Convertible Preferred Stock at $1.00 per share.
• In connection with the transaction, the company also issued 29,430,000 common stock purchase warrants (Series A, B, and C) to the investors.
• Each share of Series F Preferred Stock is convertible into 3.27 shares of common stock.
• The Series A warrants have an exercise price of $0.51 per share, Series B at $0.60 per share, and Series C at $0.68 per share, all expiring five years from issuance.
• The proceeds from the private placement will be used for general corporate and operating purposes, including investment in drug development and potential acquisitions.
• The Majority Consenting Stockholder, who holds 51.2% of the voting power and is also the Chief Executive Officer and Executive Director, approved the transaction by written consent on June 18, 2025.
• This approval includes the issuance of all common stock upon conversion of the Series F Preferred Stock and exercise of the Warrants, and an amendment to remove an Ownership Limitation, to comply with Nasdaq Listing Rule 5635(d).
• The potential issuance of 39,240,000 shares of common stock (9,810,000 from Series F conversion and 29,430,000 from Warrants) will constitute greater than 20% of the 23,759,475 shares of common stock outstanding immediately prior to the agreement.
• As of March 31, 2025, the company's estimated cash and cash equivalents were approximately $3,450,000, and there is substantial doubt regarding its ability to continue as a going concern for one year.

Sentiment

Score: 4

Explanation: While the capital raise provides essential funding to address the company's 'going concern' issues and allows for continued operations and drug development, the significant potential dilution for existing shareholders and the underlying financial distress indicate a challenging outlook. The necessity of the raise outweighs the immediate negative of dilution for company survival, but it's not a strong positive.

Positives

• Secured $3,000,000 in gross proceeds, providing crucial capital for continued operations.
• Addresses the 'going concern' doubt, allowing the company to fund its current operating plan.
• Provides capital for investment in drug development and potential acquisitions, supporting future growth initiatives.

Negatives

• The transaction involves significant potential dilution for existing shareholders, with up to 39,240,000 new common shares potentially issuable compared to 23,759,475 shares outstanding prior to the agreement.
• New investors may have rights superior to those of other stockholders, particularly regarding liquidation preferences for Series F Preferred Stock.
• The company explicitly states 'substantial doubt regarding our ability to continue as a going concern' as of March 31, 2025, indicating a precarious financial position.

Risks

• Substantial doubt regarding the ability to continue as a going concern for a period of one year.
• Significant dilution of ownership interests for existing stockholders due to the issuance of equity or convertible debt securities.
• New investors may have rights superior to the rights of other stockholders.
• Debt financing, if pursued, may involve covenants that restrict business activities and options.
• Raising additional funds through collaborations and licensing arrangements may require relinquishing valuable rights to drug discovery and other technologies, research programs, or drug candidates.
• Additional funding may not be available on favorable terms, or at all, particularly in light of current economic conditions.
• Equity valuations, including the trading price of common stock, may be depressed due to economic disruptions, rising inflationary pressures, ongoing military conflicts, or other factors, increasing the potential magnitude of dilution.

Future Outlook

The company intends to use the proceeds from the private placement for general corporate and operating purposes, investment in drug development, and potential acquisitions. It acknowledges the need to raise additional funds through various means to meet long-term financing requirements, indicating ongoing efforts to secure capital for future operations.

Management Comments

• "The board of directors believes that the Private Placement and the Series F Approval was and is necessary to provide the Company with capital for continued operations, investment in our drug development, fund our potential acquisitions and to provide the flexibility for possible future actions."
• Datuk Dr. Doris Wong Sing Ee, the Chief Executive Officer and Executive Director, is the Majority Consenting Stockholder and controls the management and affairs of the Company, including matters requiring stockholder approval.

Industry Context

This capital raise is typical for a small-cap pharmaceutical company, especially one facing 'going concern' issues, as drug development is capital-intensive with long lead times to revenue generation. Private placements are a common funding mechanism when public market access is challenging or highly dilutive. The need for Nasdaq compliance for significant share issuances is standard for listed companies, reflecting regulatory oversight on dilution and corporate governance.

Corporate Governance

Related Party Transactions

• Datuk Dr. Doris Wong Sing Ee, the Company's Chief Executive Officer and Executive Director, is identified as the Majority Consenting Stockholder, owning 12,164,301 shares of Common Stock (representing 51.2% of the total voting power) and controlling matters requiring stockholder approval. This indicates a significant related-party influence over the approved transaction.

Stakeholder Impact

• **Shareholders**: Existing shareholders face significant potential dilution as the transaction could lead to the issuance of 39,240,000 new common shares, substantially increasing the total outstanding shares and reducing their percentage ownership.
• **Company Operations**: The $3 million capital infusion is critical for the company's continued operations, drug development, and potential acquisitions, directly addressing the previously stated 'substantial doubt' about its ability to continue as a going concern.
• **New Investors**: Accredited investors gain Series F Preferred Stock and Warrants, providing them with a preferred position in liquidation and potential significant equity upside upon conversion/exercise, subject to initial ownership limitations.
• **Employees**: Continued operations supported by the capital raise likely ensures job security in the short to medium term, allowing the company to pursue its drug development programs.

Next Steps

• The actions approved by written consent will not become effective until at least 20 calendar days after the Information Statement is first mailed to stockholders (no earlier than July 27, 2025).
• The board of directors will have the authority to effect the Series F Approval after the 20-day waiting period.
• The company may continue to raise additional funds through public or private equity offerings, debt financings, or strategic alliances to meet long-term financing requirements.

Key Dates

Recommendation

Keywords

Cyclacel Pharmaceuticals, private placement, convertible preferred stock, common stock warrants, capital raise, dilution, Nasdaq compliance, going concern, biotechnology, pharmaceuticals, drug development, equity financing, SEC filing, DEF 14C